MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Lisata Therapeutics

Slēgts

2.51 -2.71

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.35

Max

2.57

Galvenie mērījumi

By Trading Economics

Darbinieki

26

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+472.52% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 11. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.3M

22M

Iepriekšējā atvēršanas cena

5.22

Iepriekšējā slēgšanas cena

2.51

Lisata Therapeutics Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. jūl. 15:29 UTC

Galvenie tirgus virzītāji

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

2025. g. 7. jūl. 23:44 UTC

Tirgus saruna

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

2025. g. 7. jūl. 23:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. jūl. 23:41 UTC

Tirgus saruna

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

2025. g. 7. jūl. 23:19 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 7. jūl. 23:19 UTC

Tirgus saruna

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

2025. g. 7. jūl. 22:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 7. jūl. 22:20 UTC

Tirgus saruna

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

2025. g. 7. jūl. 21:34 UTC

Iegādes, apvienošanās, pārņemšana

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

2025. g. 7. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. jūl. 20:45 UTC

Iegādes, apvienošanās, pārņemšana

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

2025. g. 7. jūl. 20:16 UTC

Tirgus saruna

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

2025. g. 7. jūl. 19:37 UTC

Tirgus saruna

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

2025. g. 7. jūl. 19:12 UTC

Tirgus saruna

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

2025. g. 7. jūl. 18:33 UTC

Tirgus saruna

Gold Flat as Investors Assess Market Direction -- Market Talk

2025. g. 7. jūl. 18:27 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. jūl. 16:53 UTC

Peļņas

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

2025. g. 7. jūl. 16:30 UTC

Tirgus saruna

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

2025. g. 7. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 7. jūl. 16:05 UTC

Iegādes, apvienošanās, pārņemšana

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

2025. g. 7. jūl. 15:41 UTC

Tirgus saruna

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

2025. g. 7. jūl. 15:41 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 7. jūl. 15:40 UTC

Tirgus saruna

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

2025. g. 7. jūl. 15:30 UTC

Tirgus saruna

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

2025. g. 7. jūl. 15:18 UTC

Tirgus saruna

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

2025. g. 7. jūl. 15:14 UTC

Iegādes, apvienošanās, pārņemšana

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

2025. g. 7. jūl. 15:00 UTC

Iegādes, apvienošanās, pārņemšana

GSK Completes Acquisition of Efimosfermin

2025. g. 7. jūl. 14:52 UTC

Tirgus saruna

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

2025. g. 7. jūl. 14:51 UTC

Tirgus saruna

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

2025. g. 7. jūl. 14:45 UTC

Tirgus saruna

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Salīdzinājums

Cenas izmaiņa

Lisata Therapeutics Prognoze

Cenas mērķis

By TipRanks

472.52% augšup

Prognoze 12 mēnešiem

Vidējais 15 USD  472.52%

Augstākais 15 USD

Zemākais 15 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Lisata Therapeutics — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

$

Par Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.